What are Contingent Value Rights (CVRs) in this context?

CVRs are financial instruments that were granted to certain holders as part of the Celgene acquisition. They entitle these holders to potential future payments based on the achievement of specific performance milestones, such as net sales targets for particular products like Abraxane®.

Why did Bristol-Myers Squibb file this 8-K?

The company filed this 8-K to officially notify the Trustee for the CVRs that the net sales for Abraxane® in 2022 did not trigger a payment obligation under the terms of the Contingent Value Rights Agreement.

Does this mean CVR holders will never receive a payment?

Not necessarily. This filing only confirms that no payment is due based on the 2022 Abraxane® net sales. The CVR Agreement may have provisions for future performance periods, and Bristol-Myers Squibb reserves the right to disclose if future net sales meet the required thresholds for payment.

What was the significance of the Celgene acquisition for these CVRs?

Bristol-Myers Squibb acquired Celgene in 2019. As part of the acquisition, BMY assumed the obligation to manage and potentially pay out on CVRs that were originally issued by Celgene related to its pipeline products, including Abraxane®.

BRISTOL MYERS SQUIBB CO 8-K SEC Disclosure

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K report on February 27, 2023, to provide an update regarding Contingent Value Rights (CVRs) associated with the 2019 acquisition of Celgene Corporation. The report specifically addresses the Abraxane® product and its related CVRs. Investors should note that the Company has notified the Trustee that the net sales for Abraxane in the year ended December 31, 2022, did not meet the threshold required for a Net Sales Payment under the CVR Agreement. This notification is significant as it confirms no immediate payout is due to CVR holders based on 2022 performance. The CVRs were tied to specific pipeline products of Celgene, including Abraxane, acquired as part of the broader Celgene integration. While this filing addresses the 2022 performance, BMY retains the right to disclose future Net Sales Payments if subsequent performance metrics are met and disclosed on their investor website.

Key Highlights

1Notification regarding Contingent Value Rights (CVRs) related to the Celgene acquisition.
2Focus on Abraxane® product's net sales performance for the year ended December 31, 2022.
3Reported Abraxane® net sales of $908,974,933 for the 2022 fiscal year.
4Confirmed that no Net Sales Payment is due to CVR holders for the 2022 period, as sales did not meet the CVR Agreement threshold.
5Company continues to adhere to the terms of the CVR Agreement, including potential future disclosures.
6This 8-K filing is an update on a previously announced acquisition-related obligation.

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 28, 2023)

Summary

Key Highlights

Frequently Asked Questions